Page 92 - ARNM-3-2

Advances in Radiotherapy
& Nuclear Medicine Radiotherapy in node-positive bladder cancer

Consent for publication doi: 10.1016/j.semradonc.2022.10.005

This is a retrospective analysis of patients who provided 9. Tan MP, Harris V, Warren-Oseni K, et al. The intensity-
informed consent for the treatment. No patient-identifiable modulated pelvic node and bladder radiotherapy (IMPART)
information has been used in the manuscript. trial: A phase II single-centre prospective study. Clin Oncol
(R Coll Radiol). 2020;32(2):93-100.
Availability of data doi: 10.1016/j.clon.2019.07.017

The data for this study can be obtained by submitting a 10. Griffiths G, Hall R, Sylvester R, et al. International phase
request to the lead or corresponding author. III trial assessing neoadjuvant cisplatin, methotrexate, and
vinblastine chemotherapy for muscle-invasive bladder
References cancer: Long-term results of the BA06 30894 trial. J Clin
Oncol. 2011;29(16):2171-2177.
1. National Institute for Health and Care Excellence. 2019
Surveillance of Bladder Cancer: Diagnosis and Management doi: 10.1200/JCO.2010.32.3139
(NICE guideline NG2). London: National Institute for Health 11. Søndergaard J, Høyer M, Petersen JB, Wright P, Grau C,
and Care Excellence (NICE); 2019.
Muren LP. The normal tissue sparing obtained with
2. Cancer Research UK. Bladder Cancer Statistics. Cancer simultaneous treatment of pelvic lymph nodes and bladder
Research UK; 2024. Available from: https://www. using intensity-modulated radiotherapy. Acta Oncol.
cancerresearchuk.org/health-professional/cancer-statistics/ 2009;48(2):238-244.
statistics-by-cancer-type/bladder-cancer#heading-one [Last
accessed on 2025 May 01]. doi: 10.1080/02841860802251575
12. Sherry AD, Stewart A, Luo G, Kirschner AN. Intensity-
3. Abrahamsson J, Kollberg P, Almquist H, et al. Complete
metabolic response with [18 F]fluorodeoxyglucose-positron modulated radiotherapy is superior to three-dimensional
emission tomography/computed tomography predicts conformal radiotherapy in the trimodality management
survival following induction chemotherapy and radical of muscle-invasive bladder cancer with daily cone beam
cystectomy in clinically lymph node positive bladder cancer. computed tomography optimization. J Radiat Oncol.
BJU Int. 2022;129(2):174-181. 2019;8(4):395-403.
doi: 10.1111/bju.15374 doi: 10.1007/s13566-019-00411-0
4. Afferi L, Zamboni S, Karnes RJ, et al. The impact of treatment 13. Kong V, Hansen VN, Hafeez S. Image-guided adaptive
modality on survival in patients with clinical node-positive radiotherapy for bladder cancer. Clin Oncol (R Coll Radiol).
bladder cancer: Results from a multicenter collaboration. 2021;33(6):350-368.
World J Urol. 2021;39(2):443-451. doi: 10.1016/j.clon.2021.03.023
doi: 10.1007/s00345-020-03205-z 14. Sabaa MA, El-Gamal OM, Abo-Elenen M, Khanam A.
5. Zlotta AR, Ballas LK, Niemierko A, et al. Radical cystectomy Combined modality treatment with bladder preservation for
versus trimodality therapy for muscle-invasive bladder muscle invasive bladder cancer. Urol Oncol. 2010;28(1):14-20.
cancer: A multi-institutional propensity score matched and doi: 10.1016/j.urolonc.2008.07.005
weighted analysis. Lancet Oncol. 2023;24(6):669-681.
15. Choudhury A, Swindell R, Logue JP, et al. Phase II study of
doi: 10.1016/S1470-2045(23)00170-5 conformal hypofractionated radiotherapy with concurrent
6. Choudhury A, Porta N, Hall E, et al. Hypofractionated gemcitabine in muscle-invasive bladder cancer. J Clin Oncol
radiotherapy in locally advanced bladder cancer: An 2011;29(6):733-738.
individual patient data meta-analysis of the BC2001 and doi: 10.1200/JCO.2010.31.5721
BCON trials. Lancet Oncol. 2021;22(2):246-255.
16. Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI.
doi: 10.1016/S1470-2045(20)30607-0 Radiotherapy with concurrent carbogen and nicotinamide
7. Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score in bladder carcinoma. J Clin Oncol. 2010;28(33):4912-4918.
analysis of radical cystectomy versus bladder-sparing doi: 10.1200/JCO.2010.28.4950
trimodal therapy in the setting of a multidisciplinary
bladder cancer clinic. J Clin Oncol. 2017;35(20):2299-2305. 17. James ND, Hussain SA, Hall E, et al. Radiotherapy with or
without chemotherapy in muscle-invasive bladder cancer.
doi: 10.1200/JCO.2016.69.2327
N Engl J Med. 2012;366(16):1477-1488.
8. Venkatesulu B, Liauw SL, Joshi M, et al. Multidisciplinary doi: 10.1056/NEJMoa1106106
management and radiotherapy recommendations for
clinically and pathologically node-positive bladder cancer. 18. Swinton M, Mariam NBG, Tan JL, et al. Bladder-sparing
Semin Radiat Oncol. 2023;33(1):35-50. treatment with radical dose radiotherapy is an effective

Volume 3 Issue 2 (2025) 84 doi: 10.36922/ARNM025090009